Therapeutics update скачать в хорошем качестве

Therapeutics update

WHO latest COVAX news release https://www.who.int/news/item/08-04-2... First international delivery, Ghana, 24 February 2021 Now delivered vaccines to over 100 economies So far, 38 million doses of vaccines AstraZeneca, Pfizer-BioNTech and Serum Institute of India Delays in planned deliveries for March and April As of 13th April https://www.bloomberg.com/graphics/co... 797 doses given in 154 countries Now, 18 million per day For a further 7 billion people, needing 2 doses Over two years WHO, Solidarity trials 12 000 patients in 500 hospital sites in over 30 countries https://www.who.int/emergencies/disea... found that all 4 treatments evaluated remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect on overall mortality initiation of ventilation duration of hospital stay in hospitalized patients The Solidarity Trial is considering evaluating other treatments, to continue the search for effective COVID-19 therapeutics So far, only corticosteroids have been proven effective against severe and critical COVID-19. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials https://www.who.int/news-room/feature... https://www.forbes.com/sites/jvchamar... UK bases Recovery trial https://www.recoverytrial.net https://www.bmj.com/content/370/bmj.m... Azithromycin https://www.recoverytrial.net/results... RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19 Convalescent Plasma https://www.recoverytrial.net/results... Data Monitoring Committee saw no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit Dexamethasone https://www.recoverytrial.net/files/r... Dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 Hydroxychloroquine https://www.recoverytrial.net/files/h... No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 Lopinavir-ritonavir https://www.recoverytrial.net/results... No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients Tocilizumab https://www.recoverytrial.net/results... Tocilizumab reduces deaths when given to hospitalised patients with severe COVID-19 Shortens time until patients are successfully discharged from hospital Reduces the need for a mechanical ventilator Pharmacy Magazine, ivermectin article https://www.pharmacymagazine.co.uk/iv... Introduced in 1981 Antiviral and anti-inflammatory properties Some 4 billion doses have been taken over the past 40 years Good safety record with minimal toxic effects WHO Model List of Essential Medicines as a 3mg tablet Countries now including ivermectin in their Covid-19 management strategies Greece, Bulgaria, Macedonia, Slovakia, Czech Republic Front Line Covid-19 Critical Care (FLCCC) Alliance Called for the rapid introduction of ivermectin to stem the tide of infections Prophylactic treatment can be given with two doses of 0.2mg/kg, 48 hours apart, once a month. For early out-patient treatment, a daily dose of 0.2mg/kg for a maximum of five days is recommended In the UK, the best way forward would be for the MHRA to authorise use of ivermectin for prophylaxis and treatment of Covid-19 on the basis of the published evidence to date. Next, the drug could be made available through community pharmacies either using a PGD or by making ivermectin a P medicine Ivermectin would then help to save lives and reduce suffering until the majority of the population can be vaccinated Failure to use a cheap, safe drug that reduces the severity and duration of infection as well as the risks of death and transmission seems incomprehensible Facebook, Partly false information https://healthfeedback.org/claimrevie... Current NICE guidelines https://www.nice.org.uk/guidance/ng19...